SAN ANTONIO — Fertility preservation and/or assisted reproductive technologies do not increase the risk for short-term cancer recurrence in young women with early hormone receptor (HR)-positive breast ...

Older women with high-risk hormone receptor-positive breast cancer showed no significant survival benefit from adjuvant chemotherapy 4 or 8 years later. The chemotherapy group experienced four times ...

Treatment for hormone receptorpositive (HR-positive)/HER2-negative metastatic breast cancer often starts with hormone therapy (tamoxifen or an aromatase inhibitor ...

Researchers compared clinicopathologic features, MammaPrint and BluePrint molecular subtype, and outcomes by race among patients with HR+, HER2− early-stage breast cancer.

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This ...

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings Daiichi ...

SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better ...

In a German cohort of women with hormone receptor-positive early breast cancer, more than two-thirds (68%) were adherent to their endocrine therapy regimen after 5 years, resulting in significantly ...

Please provide your email address to receive an email when new articles are posted on . Preoperative breast MRI provides no benefit in stage I or II hormone receptor-negative breast cancer. Five-year ...

An evolving understanding of the risks and benefits of HRT has led to a reevaluation of the role of HRT for breast cancer survivors.